Prime Medicine Inc (PRME)
7.43
-0.60
(-7.47%)
USD |
NASDAQ |
May 22, 16:00
7.43
0.00 (0.00%)
After-Hours: 20:00
Prime Medicine Cash from Financing (TTM): 157.91M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 157.91M |
December 31, 2023 | 0.655M |
September 30, 2023 | 184.53M |
Date | Value |
---|---|
June 30, 2023 | 183.53M |
March 31, 2023 | 182.83M |
December 31, 2022 | 181.49M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.655M
Minimum
Dec 2023
184.53M
Maximum
Sep 2023
148.49M
Average
182.16M
Median
Cash from Financing (TTM) Benchmarks
Pacific Biosciences of California Inc | -80.54M |
10x Genomics Inc | 18.72M |
Recursion Pharmaceuticals Inc | 152.11M |
Verve Therapeutics Inc | 233.27M |
Ginkgo Bioworks Holdings Inc | -3.173M |